<DOC>
	<DOC>NCT00626834</DOC>
	<brief_summary>This is a Phase 1 safety/tolerably study to determine if there are clinically significant interactions between oral vigabatrin (gamma vinyl-gamma-amino butyric acid; VGB) concurrent with intravenous (IV) cocaine infusions.</brief_summary>
	<brief_title>Vigabatrin Ph 1 Cocaine Interaction Study</brief_title>
	<detailed_description>STUDY DESIGN: This is a randomized, double-blind, placebo-controlled, parallel group study of the effects of VGB compared to placebo control on the physiological and subjective effects of IV infusions of cocaine (cocaine experienced volunteers). Subjects will be randomized within each clinical site to one of four groups (placebo control or one of three doses of VGB twice daily).During VGB steady state dosing, subjects will receive double-blind infusions of saline and cocaine. Subjects will be asked to return for follow-up approximately 7 and 14 days after the day of clinic discharge. STUDY DURATION: The maximum duration is 56 days, including 14 inpatient days of assessments and investigational products administration, and two follow-up visits after clinic discharge. SAMPLE SIZE: Twenty-four subjects will be randomized to one of three doses of vigabatrin or placebo. POPULATION: Volunteer, cocaine-experienced, non-treatment seeking cocaine users, 18 to 45 years of age.</detailed_description>
	<mesh_term>Behavior, Addictive</mesh_term>
	<mesh_term>Cocaine-Related Disorders</mesh_term>
	<mesh_term>Vigabatrin</mesh_term>
	<mesh_term>Cocaine</mesh_term>
	<mesh_term>Central Nervous System Stimulants</mesh_term>
	<criteria>Be between 18 and 45 years of age, inclusive Currently be a nontreatment seeking cocaine user as confirmed by a positive urine test for cocaine Able to provide written informed consent A negative pregnancy test within 72 hours prior to receiving the first infusion of cocaine Please contact site for more information.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>cocaine addiction</keyword>
	<keyword>vigabatrin</keyword>
	<keyword>ovation pharmaceuticals</keyword>
	<keyword>cocaine</keyword>
	<keyword>cocaine related disorders</keyword>
	<keyword>behavior addictive</keyword>
	<keyword>mental disorders</keyword>
	<keyword>therapeutic uses</keyword>
	<keyword>physiologic effects of drugs</keyword>
	<keyword>disorder of environmental origin</keyword>
	<keyword>central nervous system stimulants</keyword>
	<keyword>central nervous system agents</keyword>
	<keyword>pharmacological actions</keyword>
	<keyword>substance related disorders</keyword>
</DOC>